Gene Synthesis Upgrade GENEWIZ recently launched Gene Synthesis 2.0, signaling a strategic push to accelerate custom gene design and production. This creates a sales opportunity to upsell existing clients on the enhanced synthesis platform and to target new customers needing faster, scalable gene construction capabilities.

Multiomics Engagement Active participation in major genomics events such as Festival of Genomics and Biodata, PEGS, and ASHG indicates a focus on data-driven discoveries and translational science. Leverage these connections to position integrated solutions that combine sequencing, bioinformatics, and regulatory services for multidisciplinary research teams.

Integrated NGS and Bioinformatics GENEWIZ offers end-to-end services from DNA sequencing to bioinformatics and GLP regulatory support. This integrated stack is attractive to pharma, academia, and clinical institutions seeking single-vendor efficiency; pursue bundled deals and long-term service agreements emphasizing reduced cycle times and QA/compliance.

Global Access Network With a global footprint spanning the US, Europe, and Asia, GENEWIZ can support multinational studies and cross-border collaborations. Target pharmaceutical and biotech clients with international trials or multi-site projects by highlighting seamless global logistics, standardized workflows, and regulatory alignment.

Expansion into Protein Biomarkers The January 2025 launch of a protein biomarker detection solution leveraging Olink technology opens a doorway to adjacent diagnostics and target discovery markets. Sales conversations can focus on expanding into proteomics-enabled biomarker discovery programs and companion diagnostics collaborations.